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Approximately 1% of all men in the general population suffer from azoospermia, and azoospermic men
constitute approximately 10 to 15% of all infertile men. Thus, this group of patients represents a significant
population in the field of male infertility. A thorough medical history, physical examination and hormonal
profile are essential in the evaluation of azoospermic males. Imaging studies, a genetic workup and a testicular
biopsy (with cryopreservation) may augment the workup and evaluation. Men with nonobstructive
azoospermia should be offered genetic counseling before their spermatozoa are used for assisted reproductive
techniques. This article provides a contemporary review of the evaluation of the azoospermic male.
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& INTRODUCTION
Azoospermia is defined as the absence of sperm in at least
two different ejaculate samples (including the centrifuged
sediment) (1,2). In the general population, 10 to 15% of
couples suffer from infertility issues (3,4). Approximately
50% of these cases can be attributable to a male issue. Of
these infertile men, 10 to 20% (or 1% of all men in the
general population) suffer from azoospermia (3). A detailed
history, a physical examination, a hormone profile, imaging
and genetic counseling are important to determine the
specific clinical classification of the azoospermia. This
distinction is important given that, for example, obstructive
azoospermia (OA) and nonobstructive azoospermia (NOA)
require different treatment approaches. In this chapter, we
will provide a contemporary review of the evaluation
process for males with azoospermia.
& EVALUATION OF THE AZOOSPERMIC MALE
Definition and classification of azoospermia
Azoospermia is defined as the absence of spermatozoa in
the semen. If no spermatozoa are observed in the wet
preparation, the World Health Organization (WHO) recom-
mends an examination of the centrifuged sample (3000 X g
or greater for 15 minutes). If no sperm are observed in the
centrifuged sample, the semen analysis should be repeated.
The presence of a small number of spermatozoa in either of
the centrifuged samples is defined as cryptozoospermia,
and the complete absence of spermatozoa is defined as
azoospermia (1).
The etiologic classification of azoospermia is divided into
three primary categories: pretesticular, testicular, and post-
testicular. Although the pretesticular and post-testicular
causes of azoospermia are generally curable, the testicular
causes of azoospermia are generally not.
Pretesticular azoospermia can be caused by endocrine
abnormalities that are characterized by low levels of sex
steroids and abnormal gonadotropin levels. These abnorm-
alities can be congenital (e.g., Kallmann syndrome),
acquired (e.g., hypothalamic or pituitary disorders) or
secondary (e.g., an adverse effect from a medication).
Testicular causes include congenital, acquired or idio-
pathic disorders that lead to spermatogenic failure.
Congenital testicular causes consist of anorchia, testicular
dysgenesis (cryptorchidism), genetic abnormalities (Y chro-
mosome deletions), germ cell aplasia (Sertoli cell-only
syndrome) and spermatogenic arrest (maturation arrest).
Acquired testicular causes include trauma, torsion, infection
(mumps orchitis), testicular tumors, medications, irradia-
tion, surgery (compromising vascularization of testis),
systemic diseases (cirrhosis, renal failure) and varicocele (5).
Post-testicular causes include ejaculatory disorders or
obstructions, which impair the transport of spermatozoa
from the testis. These obstructions can also be congenital,
caused by a bilateral absence of the vas deferens (CBAVD),
or acquired because of infection or surgery (vasectomy or an
iatrogenic injury). Obstructive azoospermia (OA) is also
classified according to the localization of the obstruction:
epididymal (postinfection), vasal (vasectomy, CBAVD) or
ductal (Mu¨llerian cysts) (5).
Azoospermia may also be clinically classified as obstruc-
tive (post-testicular) and nonobstructive (pretesticular or
testicular). Obstructive azoospermia (OA) is less common
than nonobstructive azoospermia (NOA) and occurs in 15 to
20% of men with azoospermia (5). Although NOA indicates
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impaired sperm production of the entire testis by definition,
it has been observed that focal normal spermatogenesis can
be observed in 50 to 60% of men with NOA (6,7).
Semen analysis of the azoospermic male
In 2010, the WHO updated the lower reference limits for
semen characteristics, which are provided in Table 1 (1). In
the absence of vasal agenesis or testicular atrophy, semen
volume and serum FSH are key factors in determining the
cause of azoospermia. Azoospermic men with a normal
ejaculate volume may have either epididymal/vasal
obstruction or an abnormality of spermatogenesis. In such
cases, a hormonal evaluation would aid in the differential
diagnosis. Azoospermia in men with a low semen volume
and normal-sized testes can be caused by ejaculatory
dysfunction; however, the most likely cause is ejaculatory
duct obstruction (EDO) (8). Semen volume, pH and fructose
levels are generally within normal ranges in NOA; however,
these parameters can be lower in OA, depending on the
location of the obstruction. Although there are no pathog-
nomonic findings for the ejaculate evaluation of patients
with EDO, the absence of spermatozoa in a centrifuged
semen sample accompanied by a low ejaculate volume
(,2.0 ml), a pH below 7.2, and the absence of fructose in the
seminal fluid suggest EDO (9). The classic clinical presenta-
tion of EDO includes postejaculatory pain, hematospermia
and infertility. This triad of clinical presentation warrants a
transrectal ultrasound examination. The presence of dilated
seminal vesicles and/or dilated ejaculatory ducts upon
transrectal ultrasound examination, combined with a
normal hormonal profile, support a diagnosis of EDO.
A congenital bilateral absence of the vas deferens
(CBAVD) is responsible for 2 to 6% of cases of OA.
CBAVD classically presents as a nonpalpable vas segment,
low semen volume and low pH and fructose levels caused
by an obstructed epididymis and the atrophia or congenital
absence of the seminal vesicles (10,11). Nevertheless,
ejaculatory disorders and retrograde ejaculation should be
eliminated as a diagnosis for azoospermic patients with a
low ejaculate volume. A postejaculation urine evaluation
can identify patients with retrograde ejaculation.
Initial evaluation of the azoospermic male
A complete medical history, physical examination and
hormonal investigation are the principal components of the
initial evaluation of males with azoospermia (8).
Medical history
It is important to obtain a complete infertility medical
history for both partners. The azoospermic male’s history
should include such conditions as trauma, torsion, cryp-
torchidism; history of pelvic, inguinal or scrotal surgeries;
any potentially compromising testicular vascularization;
vasal patency; and ejaculatory function. Additionally, a late
onset of puberty can indicate hypogonadotropic hypogo-
nadism. Any prior fertility history can be beneficial in
distinguishing between OA and NOA. If there is a history of
vasectomy, the duration since the procedure and any
reversal attempts may be helpful in developing a treatment
plan. Genitourinary infections, such as urethritis and
epididymitis can cause OA, while late pubertal mumps
orchitis can cause NOA.
It is important to inquire about systemic diseases, given
that diabetes mellitus, cirrhosis or chronic renal insuffi-
ciency can affect sperm production or transport. Previous
malignancies, especially if treated with cytotoxic chemother-
apy or radiotherapy, should be identified. Medications that
include gonadotoxic agents, such as cimetidine, nitrofur-
antoin and calcium channel blockers, should be documen-
ted.
Physical examination
The physical examination should begin with the inspec-
tion of the body habitus, given that hair distribution,
gynecomastia and a eunuchoid stature can indicate a
testosterone deficiency or hormonal imbalance. Possible
disorders include low serum testosterone level, hyperpro-
lactinemia, abnormalities in the estrogen-to-testosterone
ratio, adrenal dysfunction, and genetic syndromes that are
associated with subvirilization, such as Klinefelter’s syn-
drome. Additionally, disproportionately long extremities
(caused by testosterone deficiency at the time of puberty,
leading to delayed closure of the epiphyseal plates) should
be noted.
The genital examination should also include an inspection
of the external genitalia. Penile curvature, hypospadias and
surgical scars should be noted. Penile curvature and
hypospadias may cause improper sperm placement into
the vagina. Surgical scars may indicate possible injuries to
the testicular blood supply and/or vas deferens.
The scrotal contents should be assessed via manual
palpation to determine the testis size and consistency and
the presence of testicular mass or asymmetry. An orchid-
ometer, calipers or sonographic measurement techniques
may be utilized to measure testicle size. The normal adult
testicle should be 463 cm or approximately 20 ml (12).
Although smaller and softer testes can signal inadequate
sperm production, men with Klinefelter’s syndrome have
small (approximately 5 ml), firm testes that are devoid of
germ cells (13). Epididymal enlargement, induration and
cysts should be assessed and can be considered a cause of
OA. The presence of the vas deferens and varicose veins
(Figure 1) should be ascertained while palpating the
Table 1 - The 2010 WHO lower reference limits (5th
percentiles and 95% confidence intervals) for semen
analysis (PR=progressive; NP=nonprogressive;
MAR=mixed antiglobulin reaction).
Parameter
Lower reference
limit (range)
Semen volume (ml) 1.5 (1.4-1.7)
Total sperm number (106 per ejaculate) 39 (33-46)
Sperm concentration (106 per ml) 15 (12-16)
Total motility (PR+NP) 40 (38-42)
Progressive motility (PR, %) 32 (31-34)
Vitality (live spermatozoa, %) 58 (55-63)
Sperm morphology (normal forms, %) 4 (3.0-4.0)
Other consensus threshold values:
pH .7.2
Peroxidase-positive leukocytes (106 per ml) ,1.0
MAR test (motile spermatozoa with bound
particles, %)
,50
Immunobead test (motile spermatozoa with
bound beads, %)
,50
Seminal zinc (mmol/ejaculate) $2.4
Seminal fructose (mmol/ejaculate) $13
Seminal neutral glucosidase (mU/ejaculate) $20
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spermatic cord. The Valsalva maneuver may aid in the
identification of low-grade varicocele. Examiners should
bear in mind that vasal agenesis may be accompanied by
genetic or renal abnormalities. The physical examination
findings for patients with CBAVD should be normal-sized
and consistent testis; full and firm caput epididymis caused
by obstructed efferent ducts (with the presence or absence of
the distal two thirds of the epididymis); nonpalpable vas
deferens; atrophic, dysfunctional or congenitally absent
seminal vesicle; and normal male external genitalia (14).
A complete physical examination of males with azoos-
permia must include a rectal examination to exclude
ejaculatory duct obstruction. Midline prostatic cysts, such
as Mu¨llerian duct cysts and dilated seminal vesicles, can be
easily palpated, and prostatic induration or tenderness
supports a diagnosis of prostatitis.
Hormonal analysis and hypogonadism
Sperm production is controlled by the hypothalamo-
pituitary-gonadal axis (Figures 2 and 3). Gonadotropin-
releasing hormone is secreted by the hypothalamus and
stimulates the anterior pituitary gland to release luteinizing
hormone (LH) and follicle stimulating hormone (FSH). LH
and FSH stimulate Leydig cells and the germinal epithelium
to produce testosterone and sperm, respectively.
Testosterone is required for the completion of the meiotic
division and spermatid development and thus plays an
important role in the initiation and maintenance of
spermatogenesis. FSH also stimulates Sertoli cells, which
produce inhibin B. LH and FSH are under negative feedback
control by testosterone and inhibin B, respectively (Figure 3)
(15).
Normal levels of LH and FSH are expected in OA;
however, LH and FSH can be low or elevated in NOA.
Hypogonadism is defined by impaired testicular function,
which potentially affects spermatogenesis and/or testoster-
one synthesis. Sussman et al. reported that the respective
incidences of hypogonadism in males who visited an
infertility clinic were 35.3%, 45% and 16.7% for those with
normal sperm analysis, NOA and OA (15). Hypogonadism
can be caused by primary testicular failure (hypergonado-
tropic hypogonadism) or secondary testicular failure
resulting from a hypothalmo-pituitary deficiency (hypogo-
nadotropic hypogonadism). Rarely, hypogonadism can
occur in complete (testicular feminization) or partial
(Reifenstein’s syndrome) androgen insensitivity syndrome.
The end organs that are affected by hypogonadism are the
external genitalia, the muscles, the bone, the skin and the
brain. The symptoms include infertility, muscular hypotro-
phy, low bone mineral density, anemia, decreased acne,
alterations in body hair distributions and decreased libido
(5,15).
In primary hypogonadism, normal or elevated LH and
FSH levels accompany low serum testosterone levels. An
FSH level greater than twice the normal upper limit is
accepted as a clear elevation of the serum FSH level, and it is
a reliable indicator of abnormal spermatogenesis (8).
However, elevated FSH in men with azoospermia does
not eliminate the possibility of obstruction and the capacity
for fertility (16). Furthermore, a stronger correlation has
been demonstrated between inhibin B and spermatogenesis
Figure 1 - Illustration of left-sided varicocele on physical
examination.
Figure 2 - Illustration of the hypothalamo-pituitary-gonadal axis,
Part 1: Regulatory pathways.
Figure 3 - Illustration of the hypothalamo-pituitary-gonadal axis,
Part 2: Feedback pathways.
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compared with FSH and spermatogenesis (17). Primary
hypogonadism can be observed in patients who exhibit
testicular failure caused by congenital (anorchia, undes-
cended testes and genetic abnormalities, such as
Klinefelter’s syndrome or Y chromosome defects), acquired
(trauma, tumor, torsion, orchitis or varicocele) or idiopathic
causes. While evaluating testosterone levels, sex hormone-
binding globulin should be considered, and an accurate
calculation of free and bioavailable testosterone should be
performed. Because of diurnal variation, blood samples
used to measure testosterone should be taken prior to 10
o’clock in the morning. The Food and Drug Administration
(FDA) defines the normal range of total testosterone levels
as between 300 and 1000 ng/dL (5,15).
Hypogonadotropic hypogonadism is characterized by
low serum FSH levels in association with low serum
testosterone levels and, generally, low LH levels.
According to a University of Illinois study, nearly half of
all men who have NOA suffer from hypogonadotropic
hypogonadism. This finding suggests that hypogonadotro-
pic hypogonadism may be considerably more prevalent in
the infertile male population than was previously believed.
Genetic hypothalamic disorders, such as Kallmann syn-
drome, and congenital or acquired pituitary deficiencies,
such as empty sella syndrome or pituitary tumors (func-
tional or nonfunctional), can cause hypogonadotropic
hypogonadism. In men who have azoospermia with
anosmia, decreased libido, gynecomastia, headaches or
visual field deficits, hypogonadotropic hypogonadism
should be suspected, and a complete endocrine work-up,
including cranial imaging, should be performed.
& IMAGING TECHNIQUES
Scrotal ultrasonography (US), transrectal US (TRUS),
TRUS-guided seminal vesiculography, seminal tract wash-
out, vasography, endorectal magnetic resonance imaging,
abdominal US and cranial imaging are all imaging studies
that can be used to evaluate males with azoospermia.
Scrotal US is a first-line, basic imaging tool for all scrotal
abnormalities, and it has also been demonstrated that
testicular volume as measured by scrotal US is significantly
correlated with testicular function. An increased resistive
index and pulsatility index of the capsular branches of the
testicular arteries on unenhanced color Doppler US exam-
ination may indicate impaired testicular microcirculation in
patients with clinical varicocele. Doppler US is a promising
method for assessing patients who are affected by azoos-
permia. This technique allows the differentiation of obstruc-
tive azoospermia (normal vessel distribution) from
nonobstructive azoospermia (reduced or absent testicular
vessels) (18). The benefit of evaluating the intratesticular
blood vessel distribution prior to the performance of any
method to retrieve intra-testicular spermatozoa for intracy-
toplasmic sperm injection has also been demonstrated (19).
When evaluating the azoospermic male to diagnose EDO,
TRUS is used for men with low ejaculate volume, but only
rarely for those with normal ejaculates (8). A dilated seminal
vesicle (anterior-posterior diameter $15 mm, Figure 4) and
anechoic areas in the seminal vesicle are the TRUS
abnormalities most frequently associated with EDO (20).
TRUS is also able to identify other known and potentially
correctable OA causes, such as Mu¨llerian (utricular)
or Wolffian (ejaculatory duct) cysts, ejaculatory duct
calcifications, congenital unilateral or bilateral absence of
the vas deferens, and obstructing seminal vesicle cysts (21).
TRUS-guided seminal vesiculography and seminal vesicle
washout are other invasive imaging techniques used to
investigate OA (22). In a prospective, comparative study,
Purohit et al. observed that TRUS has a poor specificity for
EDO evaluation when compared with vesiculography,
seminal vesicle aspiration and duct chromotubation (23).
Newly developed 3D-guided transrectal imaging devices
enable easier visualization and needle guidance for vesicu-
lography techniques (Figure 5).
The combination of azoospermia, a testis biopsy revealing
complete spermatogenesis and at least one palpable vas
deferens strongly warrant a vasography. If necessary, the
biopsy should be performed at the same time as the scrotal
exploration and the definitive repair of obstruction. Stricture
or obstruction at the vasography site, vasal blood supply
injury, hematoma and sperm granuloma are potential
complications of vasography (24).
Endorectal coil magnetic resonance imaging assesses the
relationships between the proximal prostatic urethra and
the posterior wall of the ejaculatory ducts, which must be
precisely known when endoscopic resection of the ejacula-
tory ducts is planned (25).
An azoospermic male with hypogonadotropic hypogo-
nadism may merit cranial imaging to identify hypothalamo-
pituitary disorders, especially if prolactin levels are
elevated.
Figure 4 - Transrectal imaging of the seminal vesicles.
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Abdominal US imaging should be considered if there is a
unilateral or bilateral congenital absence of the vas deferens.
Because of the embryologic origins of the vas deferens and
the kidney, anomalies in these organs tend to coexist. One
study has demonstrated that 26% and 11% of men with
unilateral or bilateral congenital absence of vas deferens,
respectively also exhibit renal agenesis (26).
Testicular biopsy
In the evaluation of azoospermic males who have normal-
sized testis and a normal hormone profile, a testicular
biopsy is critical for distinguishing between OA and NOA.
If feasible, it is best to plan for the cryopreservation of the
sperm at the same time as this procedure. In NOA, the
prognostic value of the testis biopsy is controversial.
Although many groups have not demonstrated a relation-
ship between testicular histology and sperm retrieval rate,
certain groups argue that a prior testicular biopsy may help
to determine the sperm retrieval success rate during a
follow-up procedure, such as a microTESE (testicular sperm
extraction) (27,28). It has also been demonstrated that sperm
retrieval success rates are generally high in men with
hypospermatogenesis, moderate in men with maturation
arrest and limited in men with Sertoli cell-only syndrome.
However, examiners should bear in mind that a single
testicular biopsy is not representative of the entire testicle
(29). A normal testicular biopsy implies obstruction at some
level in the sperm transport system. Diagnostic testicular
biopsies are of limited value in men with small testis size
and elevated FSH levels (greater than twice the upper limit),
which supports a diagnosis of NOA. Research recommends
that the patient undergo a microTESE (combined with
cryopreservation) in these cases and subsequent in vitro
fertilization with intracytoplasmic sperm injection (ICSI);
this procedure would enable several samples to be collected
(5,8).
A diagnostic testicular biopsy may be considered for
select azoospermic individuals who have risk factor(s) for a
testicular germ cell tumor, such as cryptorchidism, atrophic
testis and a testicular germ cell history accompanied by
testicular microlithiasis on ultrasound imaging (30). Again,
if feasible, any sperm that are detected should be cryopre-
served at the time of this biopsy.
Genetic investigation
Genetic factors occupy an important place in the evalua-
tion and management of the azoospermic male. Such factors
can be pretesticular (e.g., Kallmann syndrome), testicular
(e.g., Klinefelter’s syndrome or Y chromosome microdele-
tions) or post-testicular (CBAVD). Genetic counseling
provides couples with information about the nature,
inheritance pattern, and implications of genetic disorders
to help them make informed medical and personal
decisions. The common genetic disorders that are associated
with azoospermia are reviewed below.
Kallmann syndrome
Kallmann syndrome is an X chromosome-linked disorder
characterized by isolated gonadotropin releasing hormone
(GnRH) deficiency accompanied by complete or partial
anosmia. Six X chromosome-linked autosomal dominant
and recessive genes have been identified; of these, KAL1 is
the gene that is most commonly associated with Kallmann
syndrome. This syndrome is essentially a hormonal dis-
order in which the lack of GnRH secretion leads to testicular
insufficiency (i.e., hypogonadotropic hypogonadism) (31).
Kallmann syndrome is diagnosed clinically in the
presence of anosmia, micropenis, cryptorchidism, dimin-
ished libido, erectile dysfunction and the absence of
secondary sex characters. While serum testosterone level is
low (,100 ng/ml) in patients with Kallmann syndrome,
pituitary and hypothalamus imaging studies are normal.
Adult males with Kallmann syndrome tend to exhibit
prepubertal testicular volume (,4 ml) and have eunuchoid
body habitus caused by delayed skeletal maturation (31).
One study recently demonstrated that testicular morphol-
ogy in patients with Kallmann syndrome can vary (32).
However, spermatogenesis can be easily induced by
hormonal stimulation (5). Depending on the type of gene
mutation, nonreproductive phenotypes in men with
Kallmann syndrome can include unilateral renal agenesis,
dyskinesia and/or skeletal abnormalities, cleft lip/palate,
ear/hearing defects, coloboma (eye defect) and hyperlaxity
of the joints.
Klinefelter’s syndrome
Klinefelter’s syndrome has a wide spectrum of clinical
presentations. It is a chromosomal disorder in which at least
one additional X chromosome is observed in the male
karyotype. Although there are several mosaic forms of this
syndrome, most cases are of the nonmosaic form, 47, XXY.
Klinefelter’s syndrome is the most common chromosome
aneuploidy in human beings and the most common form of
male hypogonadism, with a prevalence of 0.1 to 0.2% in the
general population and up to 3.1% in the infertile popula-
tion. The presence of the extra X chromosome sets in motion
several undefined events that lead to spermatogenic and
androgenic failure, gynecomastia, and learning difficulties
(13,14,33). The extra X chromosome may originate from
either the maternal or paternal side.
Figure 5 - New 3D-guided transrectal imaging device (TargetScanH, Envisioneering Inc., St. Louis, MO).
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The clinical presentation of Klinefelter’s syndrome varies
according to the age at diagnosis and the severity of the
mosaicism. It is difficult to differentiate prepubertal boys
with Klinefelter’s syndrome from normal boys based solely
on their phenotype. Small, firm testes and varying symp-
toms of androgen deficiency characterize Klinefelter’s
syndrome in adolescence and after puberty (13). On one
end of the spectrum are boys who are identified as having
Klinefelter’s syndrome because they have failed to undergo
puberty and virilization as a result of nearly complete
androgenic malfunction. These boys exhibit a eunuchoid
appearance. On the opposite end of the spectrum are
phenotypically normal boys who are diagnosed with
Klinefelter’s syndrome during an evaluation for azoosper-
mia (14).
Although the exact mechanism of androgen deficiency is
unknown, most patients with Klinefelter’s syndrome exhibit
low serum testosterone concentrations and elevated FSH
levels. This reflects spermatogenic compromise and the
compensatory elevation of LH levels that results because the
Leydig cells are being maximally stimulated and have a
small reserve capacity (14). The majority of these patients
also suffer from decreased libido and erectile dysfunction.
Generally, the patients’ ejaculate presents with azoosper-
mia. A testis biopsy reveals extensive fibrosis, hyalinization
of seminiferous tubules and hyperplasia of the interstitium.
However, the tubules may exhibit residual foci of sperma-
togenesis (34).
Congenital bilateral absence of vas deference
Congenital bilateral absence of vas deference (CBAVD) is
observed in 2 to 6% of men with OA and is responsible for
infertility in approximately 1% of infertile men (10,35). A
strong association between CBAVD and the cystic fibrosis
transmembrane conductance regulator (CFTR) gene has
been demonstrated (36). This gene is located on the short
arm of chromosome 7 and encodes the CFTR protein, which
is crucial for maintaining proper sodium/chloride balance
in epithelial secretions. This balance is necessary to optimize
the viscosity and fluidity of these secretions. Approximately
1,500 different mutations of the CFTR gene have been
described. Nearly all male patients with clinically diagnosed
cystic fibrosis have CBAVD, and approximately 80% of
patients with CBAVD have mutations in at least one CFTR
allele. The inability to identify a second mutation is
presumed to result from the fact that these mutations are
located elsewhere in the noncoding regions of the CFTR
gene (5,8,37).
Cystic fibrosis (CF) is characterized by elevated concen-
trations of electrolytes in the sweat, chronic pulmonary
disease resulting from thickened respiratory epithelial
secretions and pancreatic exocrine insufficiency secondary
to thickened and occlusive ductal secretions. Both maternal
and paternal mutant alleles must be present to cause clinical
CF. However, the clinical presentation of CF depends on the
severity of the mutations in each CFTR allele and/or in the
noncoding regions of the genes (e.g., the 5T alleles). Thus,
whereas a subset of patients with CFTR mutations suffer
from severe pulmonary disease and pancreatic dysfunc-
tions, the bilateral absence of the vas deferens may be the
only observable effect in other patients (14,37).
The physical examination of the patients with CBAVD
reveals normal-sized and full testes, a full and firm caput
epididymis caused by efferent ducts that are distended with
sperm, a present or absent distal two-thirds of the
epididymis and a bilateral absence of the vas deferens.
Semen analysis reveals a low-volume (0.5 ml), acidic
ejaculate that is devoid of fructose and seminal vesicle fluid
because of atrophic, dysfunctional or absent seminal
vesicles. The seminal vesicle anomalies can be confirmed
with TRUS imaging (14). Most men with CBAVD exhibit
normal spermatogenesis, but it has been observed that a
large proportion exhibit impaired spermatogenesis. Prior to
sperm harvesting, other potential coexisting causes of
impaired spermatogenesis should be investigated (38). A
careful abdominal US should be performed because as
many as 10% of patients with CBAVDmay also exhibit renal
agenesis (26).
Y chromosome microdeletions
The relationship between deletions on the Y chromosome
and azoospermia was first recognized in 1976. With the
elucidation of the molecular anatomy of the Y chromosome,
specific microdeletions that are associated with azoospermia
or severe oligospermia were discovered in the 1990s (39).
Since this time, several case series have been published. A
study with a large number of participants demonstrated
that the prevalence of microdeletions was approximately 3%
in unselected infertile men, 8% in men with NOA and 5.5%
in men with severe OA (40). Although rare, these micro-
deletions have also been reported to occur in fertile men
(41).
Three microdeletions have been mapped to three different
regions on the long arm of the Y chromosome. These regions
are referred to as azoospermia factors (AZF)a, AZFb and
AZFc and are observed proximally, centrally and distally on
Yq11, respectively (42). Multiple genes are distributed
throughout these regions; most are involved in spermato-
genesis but are still poorly characterized. For example, the
deleted-in-azoospermia (DAZ) gene is located in the AZFc
region. This gene encodes a transcription factor that is
generally present in men with normal fertility (43). The most
frequently deleted region is AZFc (65-70%), and the least
frequently deleted region is AZFa (5%). AZFb, AZFb+c and
AZFa+b+c deletions are responsible for approximately 25 to
30% of Y microdeletions. It has been reported that Y
microdeletions are observed nearly exclusively in patients
with severe oligospermia (,1 million spermatozoa/ml) and
are extremely rare in patients with sperm concentrations .5
million spermatozoa/ml (44).
Genetic testing for Y microdeletions may predict the
outcome of sperm retrieval techniques. One study has
reported that sperm retrieval is possible in approximately
50% of patients with AZFc and partial AZFb deletions. The
same study reported that the possibility of detecting mature
spermatozoa in patients with complete AZFb deletions is
virtually zero (45). In another study, Kamp et al. demon-
strated a strong association between AZFa deletions and
Sertoli cell-only syndrome (46).
It is also important to know whether AZFc microdeletions
are present in patients with oligospermia given the evidence
of a progressive decrease in sperm count over time in such
men. The cryopreservation of spermatozoa in these cases
may avoid invasive sperm retrieval procedures in the future
(45).
Hormonal analysis (FSH and inhibin B levels) studies
have not been reliable in discriminating between patients
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with idiopathic and microdeletion-associated oligospermia
and azoospermia (44).
The male offspring of men with Y chromosome micro-
deletions are likely to inherit the same abnormality and may
also be infertile. It is unclear whether Y chromosome
microdeletions can cause additional health risks or affect
the results of assisted reproductive techniques.
Genetic counseling may be offered whenever a genetic
abnormality is suspected in either the male or the female
partner. Men with NOA should receive genetic counseling
and should be offered karyotyping and Y chromosome
microdeletion analysis before their sperm is used in assisted
reproductive techniques (8).
& EXPERT COMMENTARY
Azoospermic men constitute a significant portion of the
infertile male population. A detailed and complete medical
history, physical examination and hormonal profile are
essential in the evaluation of the azoospermic male. Imaging
studies, testicular biopsies (with cryopreservation) and
genetic testing are also important. Men with NOA should
be offered genetic counseling before their sperm is used in
assisted reproductive techniques. The accurate classification
and evaluation of the azoospermic male is important when
determining the therapeutic approach that will be chosen
for such patients.
& KEY ISSUES
a) Azoospermia is defined as the absence of sperm in at
least two different ejaculate samples (including the centri-
fuged sediment) (1,2). Ten to fifteen percent of couples in
the general population suffer from infertility issues (3,4).
Approximately 50% of these cases can be attributable to a
male issue. Ten to twenty percent of these men (or 1% of
men in the general population) suffer from azoospermia-
induced infertility (3).
b) A complete medical history, physical examination and
hormonal investigation are the principal components of the
initial evaluation of the azoospermic male (8).
c) Sperm production is controlled by the hypothalamo-
pituitary-gonadal axis (Figures 2 and 3).
d) Scrotal ultrasonography (US), transrectal US (TRUS),
TRUS-guided seminal vesiculography, seminal tract wash-
out, vasography, endorectal magnetic resonance imaging,
abdominal US and cranial imaging studies can be per-
formed when evaluating the azoospermic male.
e) In the evaluation of azoospermic patients who have
normal-sized testes and a normal hormone profile, testicular
biopsy has a critical role in distinguishing between OA and
NOA. It is best to plan for the cryopreservation of sperm at
the time of the biopsy, if feasible.
f) Diagnostic testicular biopsies are of limited value in
men with small testes and elevated FSH levels (greater than
twice the upper limit), which support a diagnosis of NOA. It
is recommended that such patients undergo a microTESE
(combined with cryopreservation) and subsequent in vitro
fertilization via intracytoplasmic sperm injection (ICSI); this
procedure would enable several samples to be taken (5,8).
g) Genetic factors are important in the evaluation and
management of azoospermic males. These factors can be
pretesticular (Kallmann syndrome), testicular (Klinefelter’s
syndrome or Y chromosome microdeletions) or post-
testicular (CBAVD). Genetic counseling provides couples
with information about the nature, inheritance patterns, and
implications of genetic disorders to help them make
informed medical and personal decisions.
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